Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins, Doug Altman, Peter C Gøtzsche et al. · BMJ · 2011 · 32.9K citations · Full text

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 11.6K citations · Full text

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.5K citations · Full text

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.4K citations · Full text

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6K citations · Full text